Article
Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
25 Jul 2025
Abstract excerpt
PURPOSE: A risk-adapted treatment strategy, the ISG/OS-2 trial, evaluated the use of mifamurtide in patients with P-glycoprotein (Pgp)-positive localized osteosarcoma. The primary objective was the identification of prognostic classifiers based on tumor microenvironment (TME) gene profiling in all patients and in those undergoing mifamurtide treatment. EXPERIMENTAL DESIGN: RNA from pretreatment formalin-fixed,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
